排序方式: 共有36条查询结果,搜索用时 15 毫秒
1.
2.
Ibrahim Aldoss MD Salman Otoukesh MD Jianying Zhang PhD Sally Mokhtari PhD Dat Ngo PharmD Mona Mojtahedzadeh MD Monzr M. Al Malki MD Amandeep Salhotra MD Haris Ali MD Ahmed Aribi MD Karamjeet S. Sandhu MD Shukaib Arslan MD Paul Koller MD Brian Ball MD Forrest Stewart MD Peter Curtin MD Andrew Artz MD Ryotaro Nakamura MD Guido Marcucci MD Stephen J. Forman MD Anthony S. Stein MD Vinod Pullarkat MD 《Cancer》2022,128(3):529-535
3.
Hermann Einsele MD Hossein Borghaei DO Robert Z. Orlowski MD Marion Subklewe MD Gail J. Roboz MD Gerhard Zugmaier MD Peter Kufer MD Karim Iskander MD Hagop M. Kantarjian MD 《Cancer》2020,126(14):3192-3201
Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small-cell lung cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments. 相似文献
4.
5.
Blinatumomab activity in a patient with Down syndrome B‐precursor acute lymphoblastic leukemia 下载免费PDF全文
Persistent minimal residual disease (MRD) after consolidation may indicate chemotherapy insensitivity in B‐precursor acute lymphoblastic leukemia (BP‐ALL). Given the strong association of MRD and outcome in non‐Down syndrome (non‐DS) BP‐ALL, it is likely that MRD levels are also of prognostic significance in DS BP‐ALL. We report here the successful use of blinatumomab, a bispecific T‐cell engager antibody construct, in a patient with DS BP‐ALL and persistent MRD at the end of consolidation. Blinatumomab has been shown to have excellent results in patients with relapsed/refractory BP‐ALL. This patient had no significant toxicity and achieved MRD negativity after only one cycle of blinatumomab. 相似文献
6.
Matthias Klinger Jonathan Benjamin Roman Kischel Sabine Stienen Gerhard Zugmaier 《Immunological reviews》2016,270(1):193-208
Bispecific T-cell engager (BiTE®) antibody constructs represent a novel immunotherapy that bridges cytotoxic T cells to tumor cells, thereby inducing target cell-dependent polyclonal T-cell activation and proliferation, and leading to apoptosis of bound tumor cells. Anti-CD19 BiTE® blinatumomab has demonstrated clinical activity in Philadelphia chromosome (Ph)-negative relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) eventually resulting in conditional approval by the U.S. Food and Drug Administration in 2014. This drug is currently further developed in pediatric and Ph+ r/r, as well as in minimal residual disease-positive ALL, and might also offer clinical benefit for patients with non-Hodgkin's lymphoma, especially for those with aggressive forms like diffuse large B-cell lymphoma. Another BiTE® antibody construct in hemato-oncology designated AMG 330 targets CD33 on acute myeloid leukemia blast cells. After showing promising ex vivo activity, this drug candidate has recently entered phase 1 clinical development, and has further indicated potential for combination with checkpoint inhibitors. In solid tumor indications, three BiTE® antibody constructs have been tested in phase 1 studies so far: anti-EpCAM BiTE® AMG 110, anti-CEA BiTE® MEDI-565/AMG 211, and anti-PSMA BiTE® BAY2010112/AMG 212. Pertinent questions comprise how to maximize BiTE® penetration and T-cell infiltration of the tumor while simultaneously minimizing any adverse events, which is currently explored by a continuous intravenous infusion approach. Thus, BiTE® antibody constructs will hopefully provide new treatment options for patients in several indications with high unmet medical need. 相似文献
7.
《Expert opinion on biological therapy》2013,13(6):761-766
Antigen-specific T cell–based immunotherapy is getting its day in the sun. The contemporaneous development of two potent CD19-specific immunotherapeutic modalities for the treatment of B-cell malignancies provides exciting opportunities for patients, physicians and scientists alike. Patients with relapsed, refractory or poor-risk B-cell acute lymphoblastic leukemia (ALL) previously had few therapeutic options and now have two potential new lifelines. Physicians will have the choice between two powerful modalities and indeed could potentially enroll some patients on trials exploring both modalities if needed. For scientists interested in tumor immunology, the advent of chimeric antigen receptor T-cell therapy and of bispecific T-cell engagers (BiTEs) provides unprecedented opportunities to explore the promise and limitations of antigen-specific T-cell therapy in the context of human leukemia. In this article, we compare chimeric antigen receptor T cells and BiTEs targeting CD19 in B-cell ALL in the setting of the available clinical literature. 相似文献
8.
9.
肿瘤免疫疗法是目前治疗肿瘤的新方向。双特异性抗体可结合两种不同的抗原,因而在肿瘤治疗领域的开发前景十分广阔。双特异性抗体中最引人注目的三功能抗体和双特异性T细胞衔接抗体已分别有药物上市,代表药物是卡妥索单抗和博纳吐单抗。迄今为止,有将近100种抗肿瘤的双特异性抗体药物正在进行临床研究,深入理解它们的作用机制将为肿瘤治疗提供更多可行的方案。本文对卡妥索单抗、博纳吐单抗和目前极具开发前景的双特异性抗体药物的研究进展进行综述,以期为在肿瘤治疗领域的开发与应用奠定基础。 相似文献
10.